Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MoonLake Immunotherapeutics MLTX

Healthcare Biotechnology
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target... see more

Recent & Breaking News (NDAQ:MLTX)

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

GlobeNewswire June 28, 2023

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

GlobeNewswire June 26, 2023

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

GlobeNewswire June 25, 2023

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire May 12, 2023

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

GlobeNewswire May 3, 2023

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

GlobeNewswire April 19, 2023

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

GlobeNewswire March 20, 2023

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

GlobeNewswire February 2, 2023

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

GlobeNewswire December 14, 2022

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

GlobeNewswire November 14, 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

GlobeNewswire September 26, 2022

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

GlobeNewswire July 26, 2022

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GlobeNewswire May 12, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Merger of Helix Acquisition Corp. with MoonLake Immunotherapeutics AG

Accesswire November 18, 2021

MERGER ALERT - ADER, DWSN, and HLXA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

Accesswire November 9, 2021

MERGER ALERT - HLXA, ITMR, and ICLK: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

Accesswire November 3, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Helix Acquisition Corp. - HLXA

PR Newswire October 30, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Helix Acquisition Corp. with MoonLake Immunotherapeutics AG

Newsfile October 4, 2021

 MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

Business Wire October 4, 2021

Helix Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Newsfile October 22, 2020